Neos Therapeutics Inc. (NASDAQ:NEOS) has been given a consensus recommendation of “Buy” by the five ratings firms that are covering the firm. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $25.33.
Separately, BMO Capital Markets reissued a “buy” rating and set a $15.00 price target on shares of Neos Therapeutics in a report on Tuesday.
In related news, CFO Richard I. Eisenstadt acquired 3,710 shares of the stock in a transaction on Thursday, August 25th. The stock was purchased at an average price of $6.82 per share, for a total transaction of $25,302.20. Following the transaction, the chief financial officer now owns 3,710 shares of the company’s stock, valued at approximately $25,302.20. The acquisition was disclosed in a filing with the SEC, which is available through this link. 4.85% of the stock is currently owned by company insiders.
Several large investors have recently modified their holdings of the company. BlackRock Fund Advisors boosted its stake in shares of Neos Therapeutics by 6.2% in the first quarter. BlackRock Fund Advisors now owns 357,058 shares of the company’s stock valued at $3,853,000 after buying an additional 20,831 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Neos Therapeutics by 5.4% in the first quarter. Geode Capital Management LLC now owns 38,698 shares of the company’s stock valued at $417,000 after buying an additional 1,997 shares in the last quarter. State Street Corp boosted its stake in shares of Neos Therapeutics by 20.0% in the first quarter. State Street Corp now owns 64,825 shares of the company’s stock valued at $698,000 after buying an additional 10,786 shares in the last quarter. ProShare Advisors LLC boosted its stake in shares of Neos Therapeutics by 10.0% in the second quarter. ProShare Advisors LLC now owns 13,622 shares of the company’s stock valued at $126,000 after buying an additional 1,233 shares in the last quarter. Finally, Perceptive Advisors LLC boosted its stake in shares of Neos Therapeutics by 526.9% in the second quarter. Perceptive Advisors LLC now owns 626,876 shares of the company’s stock valued at $4,611,000 after buying an additional 526,876 shares in the last quarter. Institutional investors own 37.73% of the company’s stock.
Shares of Neos Therapeutics (NASDAQ:NEOS) opened at 7.14 on Monday. The company has a 50 day moving average of $7.39 and a 200 day moving average of $9.01. The stock’s market cap is $114.74 million. Neos Therapeutics has a 12 month low of $6.33 and a 12 month high of $22.02.
Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings results on Thursday, August 11th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by $0.49. Neos Therapeutics had a negative net margin of 968.81% and a negative return on equity of 80.10%. The firm had revenue of $1.49 million for the quarter, compared to the consensus estimate of $1.48 million. Equities research analysts expect that Neos Therapeutics will post ($5.39) earnings per share for the current fiscal year.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.